secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2026-05-15T12:02:37+00:00
Accession:  0001339970-26-000030
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reports $68.3M cash; plans Phase 3 for efzofitimod after FDA meeting
--------------------------------------------------------------------------------

- Cash, cash equivalents, restricted cash and investments: $68.3M as of March 31, 2026.
- Plans to file IND in June 2026 for a Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease; primary endpoint FVC at week 48.
- Phase 3 study to enroll ~372 patients; randomized, double-blind, placebo-controlled, 54 weeks.
- On track to complete enrollment in Phase 2 EFZO-CONNECT study for SSc-ILD in first half 2026.
- R&D expenses $7.3M and G&A expenses $4.1M for Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/0001339970-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001339970-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer